At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CMND Clearmind Medicine, Inc.
Trading 03-10 14:47:46 EDT
1.02
+0.00
+0.29%
High1.18Low1.02Vol298.87K
Open1.02D1 Closing1.02Amplitude15.62%
Mkt Cap1.84MTradable Cap1.43MTotal Shares1.79M
T/O325.54KT/O Rate21.36%Tradable Shares1.40M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

BRIEF-Clearmind Medicine Inc - Dsmb Approves Continuation Of Phase I/Iia Cmnd-100 Trial In AUD
Reuters  ·  03-04
BRIEF-Clearmind Medicine Inc - Dsmb Approves Continuation Of Phase I/Iia Cmnd-100 Trial In AUD
Clearmind Medicine Inc - Dsmb Approves Continuation of Phase I/Iia Cmnd-100 Trial in AUD
THOMSON REUTERS  ·  03-04
Clearmind Medicine Inc - Dsmb Approves Continuation of Phase I/Iia Cmnd-100 Trial in AUD
Clearmind Medicine wins DSMB approval to advance CMND-100 AUD trial to third cohort
Reuters  ·  03-04
Clearmind Medicine wins DSMB approval to advance CMND-100 AUD trial to third cohort
Clearmind Medicine Reports Progress on MEAI as Next-Generation Weight Loss Therapy Market Shifts Beyond GLP-1 Drugs
Reuters  ·  02-20
Clearmind Medicine Reports Progress on MEAI as Next-Generation Weight Loss Therapy Market Shifts Beyond GLP-1 Drugs
Clearmind Medicine files to sell 8.17M common shares for holders
TIPRANKS  ·  02-18
Clearmind Medicine files to sell 8.17M common shares for holders
Psychedelic: Clearmind reports additional CMND-100 safety results
TIPRANKS  ·  02-12
Psychedelic: Clearmind reports additional CMND-100 safety results
BRIEF-Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile Of Cmnd-100 In Ongoing Phase I/Iia Clinical Trial
Reuters  ·  02-09
BRIEF-Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile Of Cmnd-100 In Ongoing Phase I/Iia Clinical Trial
Clearmind Medicine Reports Positive Safety Results for CMND-100 in Alcohol Use Disorder Trial
Reuters  ·  02-09
Clearmind Medicine Reports Positive Safety Results for CMND-100 in Alcohol Use Disorder Trial
Clearmind Medicine Inc - Safety Data Show No Serious Adverse Events in Second Cohort
THOMSON REUTERS  ·  02-09
Clearmind Medicine Inc - Safety Data Show No Serious Adverse Events in Second Cohort
Clearmind Medicine Inc - Announces Positive Safety Results From Phase I/Iia Trial
THOMSON REUTERS  ·  02-09
Clearmind Medicine Inc - Announces Positive Safety Results From Phase I/Iia Trial
Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial
GlobeNewswire  ·  02-09
Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial
BRIEF-Clearmind Medicine Enters Development Agreement For Intranasal Formulation Of Proprietary Nonhallucinogenic Neuroplastogen MEAI
Reuters  ·  02-06
BRIEF-Clearmind Medicine Enters Development Agreement For Intranasal Formulation Of Proprietary Nonhallucinogenic Neuroplastogen MEAI
BUZZ-Polyrizon jumps as it teams up with Clearmind for intranasal drug delivery
Reuters  ·  02-06
BUZZ-Polyrizon jumps as it teams up with Clearmind for intranasal drug delivery
Clearmind Medicine Enters Into Development Agreement to Advance Intranasal Formulation for Its Proprietary Non-Hallucinogenic Neuroplastogen Meai
THOMSON REUTERS  ·  02-06
Clearmind Medicine Enters Into Development Agreement to Advance Intranasal Formulation for Its Proprietary Non-Hallucinogenic Neuroplastogen Meai
Polyrizon Partners with Clearmind to Develop Intranasal MEAI Formulation
Reuters  ·  02-06
Polyrizon Partners with Clearmind to Develop Intranasal MEAI Formulation
Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation
THOMSON REUTERS  ·  02-06
Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation
Clearmind Medicine Issues $2.5 Million in Convertible Promissory Notes
Reuters  ·  02-05
Clearmind Medicine Issues $2.5 Million in Convertible Promissory Notes
Clearmind Medicine gibt Ausgabe von Wandelanleihen im Gesamtwert von 2,5 Millionen US-Dollar bekannt
Reuters  ·  02-05
Clearmind Medicine gibt Ausgabe von Wandelanleihen im Gesamtwert von 2,5 Millionen US-Dollar bekannt
Clearmind Medicine welcomes inclusion of MEAI in bipartisan legislation
TIPRANKS  ·  02-03
Clearmind Medicine welcomes inclusion of MEAI in bipartisan legislation
Clearmind Medicine erzielt Durchbruch mit MEAI in US-Gesetz für innovative Veteranen-Therapien
Reuters  ·  02-03
Clearmind Medicine erzielt Durchbruch mit MEAI in US-Gesetz für innovative Veteranen-Therapien

Introduction

Company Name.
Clearmind Medicine, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company has a collaboration with Clearmind Medicine Inc. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.
Issue price:
--